These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 30105645)

  • 1. The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer.
    Gomes F; Tay R; Chiramel J; Califano R
    Drugs Aging; 2018 Sep; 35(9):819-834. PubMed ID: 30105645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
    Nagano T; Tachihara M; Nishimura Y
    Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
    Ferrara R; Mezquita L; Auclin E; Chaput N; Besse B
    Cancer Treat Rev; 2017 Nov; 60():60-68. PubMed ID: 28889085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.
    Calles A; Riess JW; Brahmer JR
    Am Soc Clin Oncol Educ Book; 2020 May; 40():372-384. PubMed ID: 32421452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Personalized therapy of lung cancer - current standard and future challenges].
    Riedel R; Wolf J
    Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
    Meoni G; Cecere FL; Lucherini E; Di Costanzo F
    J Geriatr Oncol; 2013 Jul; 4(3):282-90. PubMed ID: 24070465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy and Immunotherapy for Lung Cancer.
    Naylor EC; Desani JK; Chung PK
    Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Mhanna L; Guibert N; Milia J; Mazieres J
    Curr Treat Options Oncol; 2019 Jun; 20(7):60. PubMed ID: 31172347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapies for Lung Cancer.
    Stinchcombe TE
    Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
    Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M
    Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.
    Lo Russo G; Imbimbo M; Garassino MC
    Tumori; 2016 Jun; 2016(3):223-5. PubMed ID: 26979246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for Immunotherapy.
    Bustamante-Alvarez JG; Owen DH
    Thorac Surg Clin; 2020 May; 30(2):207-214. PubMed ID: 32327179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological therapies in nonsmall cell lung cancer.
    Zugazagoitia J; Molina-Pinelo S; Lopez-Rios F; Paz-Ares L
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28254765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in targeted advanced lung cancer therapy in the elderly.
    Losanno T; Gridelli C
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):787-797. PubMed ID: 28656792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
    Alden RS; Mandrekar SJ; Oxnard GR
    Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?
    Gardiner RE; Jahangeer S; Forde P; Ariffin AB; Bird B; Soden D; Hinchion J
    Cancer Metastasis Rev; 2015 Mar; 34(1):129-44. PubMed ID: 25726003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?
    Casaluce F; Gridelli C
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):121-127. PubMed ID: 37144331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined Therapy with Targeted Drugs in Lung Cancer].
    Yano S
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):413-8. PubMed ID: 27220787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.